

| | | | | | | | |
|--|----|---|----------|---|--|--|-------------------------------|
| Form PTO 1449 (Modified) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY DOCKET NO. 281383US0X PCT | | SERIAL NO. 10/557,602 | |
| LIST OF REFERENCES CITED BY APPLICANT | | | | APPLICANT Shigeyuki KON, et al. | | | |
| | | | | FILING DATE November 13, 2006 | | GROUP 1644 | |
| | | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |
| | AL | | | | | | |
| | AM | | | | | | |
| | AN | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | TRANSLATION YES NO | | |
| | AO | 01/71358 | 09/27/01 | WIPOI | | | |
| | AP | | | | | | |
| | AQ | | | | | | |
| | AR | | | | | | |
| | AS | | | | | | |
| | AT | | | | | | |
| | AU | | | | | | |
| | AV | | | | | | |
| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | |
| | AW | D. HONGYAN, et al. "Osteopontin as a Mediator of NKT Cell Function in T Cell-Mediated Liver Diseases" Immunity, Vol. 21, pp. 539-550, October (2004) | | | | | |
| | AX | J. SODEK, et al. "Osteopontin" "Critical Reviews in Oral Biology and Medicine" Vol. 11, No. 3, January 1, 2000, pp. 279-303, XP001022167 | | | | | |
| | AY | D.S. BAUTISTA, et al., "A Monoclonal Antibody Against Osteopontin Inhibits RGD-Mediated Cell Adhesion to Osteopontin" Annals of the New York Academy of Sciences, Vol. 76, April 21, 1995, pp. 309-311, XP009033073 | | | | | |
| | AZ | Y. NOBUCHIKA, et al., "Essential Role of the Cryptic Epitope Slayglr within Osteopontin in a Murine Model of Rheumatoid Arthritis", Journal of Clinical Investigation, Vol. 112, No. 2, July 2003, pp. 181-188, XP002507479 | | | | <input type="checkbox"/> Additional References sheet(s) attached | |
| Examiner | | | | | | | |
| | | Date Considered | | | | | |
| *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
281383US0X PCTSERIAL NO.
10/557,602

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT
Shigeyuki KON, et al.FILING DATE
November 13, 2006GROUP
1644

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|---------------------|----|--------------------|------|------|-------|--------------|-------------------------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |
| | AL | | | | | | |
| | AM | | | | | | |
| | AN | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | TRANSLATION | |
|--|----|--------------------|------|---------|-------------|----|
| | | | | | YES | NO |
| | AO | | | | | |
| | AP | | | | | |
| | AQ | | | | | |
| | AR | | | | | |
| | AS | | | | | |
| | AT | | | | | |
| | AU | | | | | |
| | AV | | | | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

| | |
|----|---|
| AW | S. KON, et al., "Mapping of Functional Epitopes of Osteopontin by Monoclonal Antibodies Raised Against Defined Internal Sequences" Journal of Cellular Biochemistry, Vol. 84, No. 2, October 15, 2001, pp. 420-432, XP002961001 |
| AX | Nat. Clin. Pract. Gastroenterol Hepatol., Montano Loza AJ., et al., "Current Therapy for Autoimmune Hepatitis", 2007 April, 4(4):202-14. (Abstract Only) |
| AY | Dig Dis Sci., Wolf DC., et al. "Mycophenolate Mofetil for Autoimmune Hepatitis: A Single Practice Experience", 2008 Dec 12 (Abstract Only) |
| AZ | Am J Gastroenterol, Fernandes NF., et al. "Cyclosporine Therapy in Patients with Steroid Resistant Autoimmune Hepatitis", 1999 Jan, 94(1):241-8 (Abstract only) |

☐ Additional References sheet(s) attached

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

281383US0X PCT

SERIAL NO.

10/557,602

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Shigeyuki KON, et al.

FILING DATE

November 13, 2006

GROUP

1644

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|---------------------|----|--------------------|------|------|-------|--------------|-------------------------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |
| | AL | | | | | | |
| | AM | | | | | | |
| | AN | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | TRANSLATION | |
|--|----|--------------------|------|---------|-------------|----|
| | | | | | YES | NO |
| | AO | | | | | |
| | AP | | | | | |
| | AQ | | | | | |
| | AR | | | | | |
| | AS | | | | | |
| | AT | | | | | |
| | AU | | | | | |
| | AV | | | | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

| | | |
|--|----|--|
| | AW | Can J Gastroenterol, Zandie I. Krygier D. et al., "The Use of Budesonide in the Treatment of Autoimmune Hepatitis in Canada", 2008 April; 22(4):388-92 (Abstract Only) |
| | AX | |
| | AY | |
| | AZ | |

☐ Additional References sheet(s) attached

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.